EGFR and non-small cell lung carcinoma: Instead of examining EGFR mutant NSCLC cells that are sensitive to EGFR inhibition, they utilized H1650 cells, which, despite bearing an in-frame exon 19 deletion mutation in EGFR, are TKI-insensitive.